Shield HealthCare has sold a majority interest to Henry Schein
Shield Healthcare has sold a majority ownership position to Henry Schein, Inc. (NASDAQ: HSIC), the world’s largest provider of healthcare solutions to office-based dental and medical practitioners.
Founded in 1957 and headquartered in Valencia, California, Shield is one of the largest independent value-added distributors of essential medical supplies for patients and caregivers managing care in the home. The company’s diversified product catalog includes durable and consumable medical products for a wide range of patient diagnoses, including incontinence, enteral nutrition, ostomy, urology and advanced wound care. Shield operates across a nationwide footprint to provide superior solutions centered around improving patient outcomes and providing exceptional customer service and patient satisfaction.
Henry Schein is a solutions company for healthcare professionals powered by a network of people and technology. With approximately 24,000 members worldwide, the company’s network of trusted advisors provides over one million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes. Its business, clinical, technology and supply chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional healthcare clinics, as well as other alternate care sites.
Oaklins Intrepid in Los Angeles acted as the exclusive sell-side advisor in this transaction.
Contáctese con el equipo de la transacción
Adam Abramowitz
Oaklins Intrepid
Transacciones relacionadas
Medicija has acquired Saulės Šeimos Medicinos Centras
Medicija has acquired a 100% stake in Saulės Šeimos Medicinos Centras.
Aprenda másQuimpharma has completed the divestiture of a product portfolio to Megalabs
Quimpharma has completed the divestiture of a product portfolio to Megalabs México.
Aprenda másIXICO has completed a fundraising
IXICO plc, a specialist in AI-driven neuroimaging analytics, has completed a US$13.5 million gross capital raise. The funds will be used to support the company’s tech bio strategy, which will see IXICO partner its platform to maximize its potential.
Aprenda más